Many researches aiming to explore the pathogenesis of lung cancer have extensively studied the molecular alteration in such disease.
OBJECTIVE:
In the present study we measured the blood E2F3 mRNA using real-time RT-PCR technique in order to evaluate its clinical significance in early diagnosis and monitoring of lung cancer.
METHODS:
This case-control study included 50 lung cancer patients, 20 patients with benign lung diseases and 20 healthy controls. Relative quantification of blood E2F3 mRNA was done by real-time RT-PCR.
RESULTS:
Blood E2F3 mRNA levels were significantly higher in lung cancer patients when compared to either patients with benign lung diseases or healthy subjects. This elevation was significant in those with metastatic lung cancer as compared to those with localized lung cancer. At a cutoff^{(2-Δ Δ CT)} 1.5, blood E2F3 mRNA was able to distinguish malignant from benign lung conditions with a diagnostic sensitivity of 100%; while at a cutoff^{(2-Δ Δ CT)} 5.3, blood E2F3 mRNA discriminated localized from metastatic lung cancer with a sensitivity of 93.6%.
CONCLUSIONS:
Blood E2F3 mRNA is a sensitive diagnostic marker in lung cancer; moreover, it is a promising prognostic marker capable of efficiently discriminating early from late stages of the disease.
ZhaoF.Y., HanJ., ChenX.W., WangJ., WangX.D., SunJ.G. and ChenZ.T., miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor. Int J Mol Med38 (2016), 183-191.
2.
KarimiS., MohamadniaA., NadjiS.A., YadegarazariR., KhosraviA., BahramiN. and SaidijamM., Expression of two basic mRNA biomarkers in peripheral blood of patients with non-small cell lung cancer detected by Real-Time RT-PCR, individually and simultaneously. Iran Biomed J19 (2015), 17-22.
3.
UrmanA. and HosgoodH.D., Curbing the burden of lung cancer. Front Med10 (2016), 228-232.
4.
WangX., MaK., ChiL., CuiJ., JinL., HuJ.F. and LiW., Combining telomerase reverse transcriptase genetic variant rs2736100 with epidemiologic factors in the prediction of lung cancer susceptibility. Cancer7 (2016), 846-853.
5.
HuntingtonJ.T., TangX., KentL.N., SchmidtC.R. and LeoneG., The spectrum of E2F in liver disease- mediated regulation in biology and cancer. J Cell Physiol231 (2016), 1438-1449.
6.
ZhanL., ZhangY., WangW., SongE., FanY. and WeiB., E2F1: A promising regulator in ovarian carcinoma. Tumour Biol37 (2016), 2823-2831.
7.
ParkS.A., PlattJ., LeeJ.W., López-GiráldezF., HerbstR.S. and KooJ.S., E2F8 as a novel therapeutic target for lung cancer. J Natl Cancer Inst107 (2015), doi: 10.1093/jnci/djv151.
8.
KurtykaC.A., ChenL., and CressW.D., E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLOS ONE9 (2014), e96357.
9.
RotgersE., Rivero-MüllerA., NurmioN., ParvinenM., GuillouF., HuhtaniemiI., KotajaN., Bourguiba-HachemiS. and ToppariJ., Retinoblastoma protein (RB) interacts with E2F3 to control terminal differentiation of Sertoli cells. Cell Death and Dis5 (2014), e1274.
10.
VimalaK., SundarrajS., SujithaM.V. and KannanS., Curtailing overexpression of E2F3 in breast cancer using siRNA (E2F3)-based gene silencing. Arch Med Res43 (2012), 415-422.
11.
SenguptaS. and HenryR.W., Regulation of the retinoblastoma-E2F pathway by the ubiquitin-proteasome system. Biochim Biophys Acta1849 (2015), 1289-1297.
12.
RoskoskiR., Jr., Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol Res107 (2016), 249-275.
13.
ZengX., YinF., LiuX., XuJ., XuY., HuangJ., NanY. and QiuX., Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma. Oncol Rep31 (2014), 1139-1146.
14.
AnQ., WangY., AnR., LiY., YaoT., ZhaiB. and SunX., Association of E2F3 expression with clinicopathological features of Wilms' tumors. J Pediatr Surg48 (2013), 2187-2193.
15.
ChangS.W., YueJ., WangB.C. and ZhangX.L., miR-503 inhibits cell proliferation and induces apoptosis in colorectal cancer cells by targeting E2F3. Int J Clin Exp Pathol8 (2015), 12853-12860.
16.
CooperC.S., NicholsonA.G., FosterC., DodsonA., EdwardsS., FletcherA., RoeT., ClarkJ., JoshiA., NormanA., FeberA., LinD., GaoY., ShipleyJ. and ChengS.J., Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Lung Cancer54 (2006), 155-162.
ChenH.Z., TsaiS.Y. and LeoneG., Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer9 (2009), 785-797.
19.
ChenL., KongG., ZhangC., DongH., YangC., SongG., GuoC., WangL. and YuH., MicroRNA-432 functions as a tumor suppressor gene through targeting E2F3 and AXL in lung adenocarcinoma. Oncotarget7 (2016), 20041-20053.
20.
KanaiD., UedaA., AkagiT., YokotaT., and KoideH., Oct3/4 directly regulates expression of E2F3a in mouse embryonic stem cells. Biochem Biophys Res Commun459 (2015), 374-378.
21.
GaoY., LiH., MaX., FanY., NiD., ZhangY., HuangQ., LiuK., LiX., WangL., YaoY., AiQ. and ZhangX., E2F3 upregulation promotes tumor malignancy through the transcriptional activation of HIF-2a in clear cell renal cell carcinoma. Oncotarget (2016), doi: 10.18632/oncotarget.10568. [Epub ahead of print].
22.
HamiltonG., RathB. and UlspergerE., How to target small cell lung cancer. Oncoscience2 (2015), 684-692.
23.
MederL., KönigK., OzretićL., SchultheisA.M., UeckerothF., AdeC.P., AlbusK., BoehmD., Rommerscheidt-FussU., FlorinA., BuhT., HartmannW., WolfJ., Merkelbach-BruseS., EilersM., PernerS. and BuettnerR., NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. J Cancer138 (2016), 927-938.
24.
SunC., LiS., ZhangF., XiY., WangL., BiY., and LiD., Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. Oncotarget (2016), doi: 10.18632/oncotarget.10108. [Epub ahead of print].
25.
WuL., de BruinA., WangH., SimmonsT., CleghornW., GoldenbergL.E., SitesE., SandyA., TrimboliA., FernandezS.A., EngC., ShapiroC.C. and LeoneG., Selective roles of E2Fs for ErbB2- and Myc-mediated mammary tumorigenesis. Oncogene34 (2015), 119-128.
26.
LeeJ.M., HeoM.J., LeeC.G., YangY.M. and KimS.G., Increase of miR-199a-5p by protoporphyrin IX, a photocatalyzer, directly inhibits E2F3, sensitizing mesenchymal tumor cells to anti-cancer agents. Oncotarget6 (2015), 3918-3931.
27.
GaoY., LiH., MaX., FanY., NiD., ZhangY., HuangQ., LiuK., LiX., WangL., YaoY., AiQ. and ZhangX., E2F3 upregulation promotes tumor malignancy through the transcriptional activation of HIF-2a in clear cell renal cell carcinoma. Oncotarget (2016), doi: 10.18632/oncotarget.10568. [Epub ahead of print]
28.
PipinikasC.P., NairS.B., KirbyR.S., CarterN.D., and FenskeC.D., Measurement of blood E2F3 mRNA in prostate cancer by quantitative RT-PCR: A preliminary study. Biomarkers12 (2007), 541-557.
29.
DavidsonM.R., GazdarA.F. and ClarkeB.E., The pivotal role of pathology in the management of lung cancer. J ThoracSuppl 5 (2013), S463-S478.
